BioProgress plc, the speciality pharma and healthcare company, announces the launch of a further two new products within its US portfolio through its subsidiary Dexo LLC.
The first of these is SymPak, a combination of two of Dexo's popular cough and cold products, Sinuvent PE and Omnihist II LA. Each SymPak contains a 2-week regimen of 2 Sinuvent PE tablets daily for the morning dose, and 1 Omnihist II LA tablet daily for the evening dose. The product was released in response to physician research that indicated a need for a product tailored to the active lifestyle of many working adults.
The product is designed to deliver a strong dose of antihistamine (Phenylephrine HCl) and expectorant (Guaifenesin) in the morning without any sedating effects to the active patient; then in the evening, it delivers a full dose of the same antihistamine coupled with a strong decongestant (Chlorpheniramine Maleate) and drying agent (Methscopolamine Nitrate). SymPak will be marketed as a single prescription, alternative to treat a full range of symptoms.
The second product is a liquid line extension of the Ah-Chew range Ah-Chew Syrup, a 4 times per day product, to its popular Ah-Chew line of products intended to treat cough and cold symptoms. Ah-Chew Syrup will be priced very competitively with over-the-counter cough and cold remedies while providing symptom relief from prescription-only quantities of active ingredients.
Both of the new products will be new entrants in the expanding US $25bn domestic cough cold market, and will be available throughout the US and supported by Dexo"s sales force. It is anticipated that the products will be launched in other countries subject to regulatory approvals.
Steve Martin, chief development officer said, "The launch of these two new products into the US market is further proof of BioProgress's commitment to build a healthy innovative specialty pharmaceutical business. We are pleased to continue our aggressive launch of new products into the market with the expectation of further launches over the coming months. The company is pushing ahead with the integration of its technology with these core brands in order to generate sustainable revenue streams."